Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update by Portelius, E et al.
Proteomic studies of cerebrospinal fluid biomarkers for Alzheimer's disease: an update 
 
Erik Portelius1,2, Gunnar Brinkmalm1,2, Josef Pannee1,2, Henrik Zetterberg1,2,3,4, Kaj 
Blennow1,2, Rahil, Dahlén1,2, Ann Brinkmalm1,2, Johan Gobom1,2 
 
1 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, 
the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden 
 
2 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden 
 
3 Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, 
WC1N London UK. 
 
4 UK Dementia Research Institute, WC1N London UK 
 
Corresponding author 
Erik Portelius 
Clinical Neurochemistry Laboratory 
Sahlgrenska University Hospital 
University Hospital 
SE-431 80 Mölndal 
Sweden 
Email: erik.portelius@neuro.gu.se 
Phone: +46 31 343 23 90 
 
Abstract: approximately 120 words. 
Alzheimer’s disease (AD) is a neurodegenerative disease affecting the brain. Today there are 
three cerebrospinal fluid (CSF) biomarkers, amyloid-β consisting of 42 amino acids (Aβ42), 
total-tau (t-tau) and phosphorylated-tau (p-tau), which combined have sensitivity and 
specificity figures around 80%. In the current paper, we screened PubMed for articles 
published the last five years (2012-2017) on proteomic studies on CSF with the criteria that 
AD had to be included as one of the diagnostic groups. Based on inclusion criteria, XX papers 
were included. Both mass spectrometry and multi-panel immunoassays were considered as 
proteomic studies. A large number of pilot data have been reported but so far there is a lack of 
replicated findings and to date no CSF biomarker discovered in proteomic studies has reached 
the clinic to aid in the diagnostic work-up of patients with cognitive impairment. 
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Introduction 
Alzheimer’s disease (AD) is a disorder affecting the structure and function of the human 
brain, leading to episodic memory impairment and general cognitive symptoms including 
difficulties in decision-making and orientation. The disease was first described by Alois 
Alzheimer in 1906 and is today the most prevalent form of dementia accounting for 50-60% 
of all cases [1,2]. Alzheimer described brain changes, including extracellular “miliary bodies” 
(plaques), “dense bundles of fibrils” (tangles) in the interior if nerve cells and degeneration of 
cortical nerve cells, in a patient with early onset dementia. These changes are now considered 
the neuropathological hallmarks of AD [2]. Nearly 80 years later, Colin Masters and 
colleagues isolated plaques from AD and Down’s syndrome patients and were able to show 
that one of the major components of the plaques was cerebral amyloid protein which today is 
called amyloid β (Aβ) [3]. Almost at the same time it was shown that paired helical filaments, 
isolated from brains of AD patients, consist of the microtubule-associated protein tau [4,5]. 
These two breakthroughs can be considered as the start of the “modern” AD research which 
also forms the basis for the amyloid cascade hypothesis. According to this hypothesis, AD is 
caused by abnormal accumulation of Aβ in senile plaques in the brain. This process is thought 
to induce, by unknown mechanisms, hyperphosphorylation of the axonal protein tau, 
formation of intra-neuronal tau inclusions (neurofibrillary tangles), neurodegeneration and, 
ultimately, dementia [6]. 
 
The core biomarkers of Alzheimer’s disease 
In 1992, it was shown that Aβ is present in cerebrospinal fluid (CSF) [7] and a few years later 
it was demonstrated that AD patients have a lower concentration of a 42 amino acid long Aβ 
peptide (Aβ42) compared to healthy controls [8] which is believed to reflect the plaque 
pathology [9]. The first publication demonstrating a marked increase in CSF total-tau (t-tau) 
and phosphorylated tau (p-tau) in AD was published 1995 [10]. Today, several studies have 
shown that Aβ42 in combination with t-tau p-tau can be used to diagnose AD with sensitivity 
and specificity around 85-95%  [11]. They are referred to as the core biomarkers because they 
all are at the core of the disease pathology (plaque and tangles), and they are since 2007 
included in the diagnostic research criteria for AD [12] and in the International Working 
Group (IWG-2) research diagnostic criteria [13]. Lately they have also more frequently been 
used as inclusion criteria to clinical trials where drugs that may have disease-modifying 
effects are tested. 
 
Other pathologies associated with Alzheimer’s disease 
With all the pathological studies published on AD up to date, it is safe to conclude that 
comorbidity (the presence of more than one disease process) is present in more than half of 
the AD patients [14]. Below follows some examples of such pathologies. 
 
In 2006, the TAR DNA-binding protein 43 (TDP-43) was identified to be a major constituent 
of protein aggregates in the brains of patients diagnosed with fronto-temporal lobar 
degeneration (FTLD) [15]. In addition, TDP-43 has been suggested to cause 
neurodegeneration. Recent pathological studies have shown that TDP-43 seems to be a 
secondary feature of several neurodegenerative diseases, including AD and Parkinson disease 
(PD). Indeed, TDP-43 pathology has been found to be associated with amyloid plaques and 
tangles and studies have shown that TDP-43 pathology is found in over 50% of AD cases. 
One of the forms of cerebral amyloid angiopathy (CAA), a disease characterized by 
accumulation of amyloidogenic proteins in cerebral arteries, arterioles and capillaries, 
displays aggregated Aβ and previous studies have shown that 25% of the AD patients also 
have CAA. α-Synuclein, a protein which strongly associated with PD and dementia with 
Lewy bodies (LBD), has been shown to aggregate into so called Lewy bodies which develop 
inside nerve cells. Several pathological studies have demonstrated that α-synuclein pathology 
can be found in multiple brain regions in almost 50% of the AD cases. Mounting evidence has 
indicated that synaptic dysfunction is an event that occurs early in the disease progression, 
earlier than the plaque and tau pathology. The synaptic pathology including synaptic 
degeneration and loss is widespread in the AD effected brain. Several studies have shown that 
activation of inflammatory pathways is a common feature in AD and local inflammations in 
the brain are common pathological findings as comorbidity in the AD affected brain. In 
conclusion, there are numerous comorbidities associated with AD and several, such as LBD, 
vascular brain injury, hippocampal sclerosis and TDP-43 inclusions, have been shown to 
contribute to cognitive impairment. 
 
Why do we need additional biomarkers for AD? 
A disease biomarker should reflect the activity of a disease process and ideally be used for 
diagnosis and prognosis in clinical practice, selection of patients into clinical trials and as a 
pharmacodynamic marker. It is clear that the three core CSF biomarkers Aβ42 in combination 
with t-tau and p-tau is not enough to identify “pure AD”. In order to identify these patients, 
we are in great need of additional biomarkers reflecting other pathologies besides the plaque 
and tau pathology. This will most likely be of outmost importance the day we have a therapy 
for AD with disease modifying effects, e.g., vaccination and secretase inhibitors. In the 
present paper, we have examined the literature on what have been published the last 
five years covering proteomic studies on CSF biomarkers for AD. Articles published in 
PubMed between 2012 and March 2017 were screened with the following search string; 
cerebrospinal fluid; Alzheimer’s disease, proteomics; mass spectrometry; 
xxxxxxxxxxxxxx. The published paper had to include at least one biomarker which could 
be analyzed either using mass spectrometry or immunoassay in a panel format. 
Approaches to biomarker discovery and development 
Explorative proteomic studies 
In the emerging field of clinical proteomics, the basic premise is to compare, on a global 
level, protein abundances in clinical cohorts to detect proteins that differ between study 
groups, for example between disease groups or treatment groups. A particularly attractive 
aspect of the unbiased proteomic approach is that it may lead to the discovery of biomarkers 
that are not based on existing hypotheses, thereby stimulating the formulation of new 
hypotheses on disease mechanisms.  
Identifying biomarkers in CSF is, however, a challenging task for several reasons. The uneven 
distribution of protein concentrations, with the protein content being heavily dominated by a 
small number of highly abundant proteins, hampers the detection of low-abundant proteins. 
Furthermore, heterogeneous disease groups and individual proteome variations necessitates 
the analysis of large cohorts in order to discern disease-associated aberrancies. Thus, a 
particular challenge of CSF proteomics is to achieve sufficient depth of analysis, demanding 
sample prefractionation and long analysis times per sample, while also acquiring quantitative 
information from a sufficient number of study participants. Different analytical strategies are 
currently being explored to address this challenge. 
Label-free quantification 
The majority of explorative proteomic studies in CSF published in the last five years use the 
label-free (LF) approach. The simplest form of LF quantification is spectral counting, in 
which protein abundances are measured as the count of acquired fragment ion spectra in 
liquid chromatography-mass spectrometry (LC-MS) data sets, which were matched by 
database searching to tryptic peptides of the given protein (ref.). Alternatively, LF 
quantification can be based on the peak area of the precursor ion in the preceding MS scan or, 
more sophisticated, by mass spectrometric feature detection of peptide precursors over their 
high pressure liquid chromatography (HPLC) elution profile (ref. OpenMS, Non-linear 
dynamics). Attractive feature of LF quantification is that it involves relatively little sample 
preparation, and that peptides are detected in their native state, thus facilitating the 
establishment of selected reaction monitoring (SRM) assays. 
Perrin et al. evaluated the performance of the LF approach by analysis of pooled and 
individual CSF samples [14]. While they reported low variability for a subset of 87 proteins 
they also pointed out some methodological limitations. One such limitation is the fluctuations 
of the signal response of the LC-MS system over time, which, in the absence of an internal 
standard, may affect quantification. Since sample multiplexing is not possible with the LF 
approach, this problem is likely to hamper larger clinical studies, as they require consistent 
LC-MS performance over several days or even weeks. This is likely one reason why CSF 
biomarker studies using the LF approach are typically quite small (10-20 patients), and the 
identified proteins are used primarily to select candidate markers for targeted follow-up 
studies. For example, in a discovery study of LBD in which LF quantification to analyze a 
cohort comprised of 10 patients and 15 controls a panel of 26 candidate biomarkers was 
identified, for which targeted SRM assays were established [16]. This panel was then assayed 
in a second cohort of similar size, consisting of AD, Parkinson’s disease (PD) and DLB 
patients and controls, identifying four novel protein markers; ENPP2, transthyretin, Pro-
orexin and LAMP1, that were elevated in AD compared to the other groups, and several 
proteins that were elevated in all disease groups. They also found several markers for LBD, 
and validated the data in LBD, AD, PD and controls [16]. 
A similar approach was used in a discovery study to identify AD biomarkers in a cohort 
consisting of 10 AD patients and 10 non-demented controls [17]. Two candidate markers; 
neurosecretory protein VGF and NPTXR, were selected among the identified proteins and 
assayed in a second cohort consisting of longitudinal samples. 
Also using LF proteomics, the CSF proteome of 14 persons who will develop AD due to 
mutations in the PSEN1 and APP genes was compared, with five related non-mutation 
carriers, identifying 56 proteins that differed between the groups [18]. Similarly, the 
proteomes of 12 frontotemporal dementia (FTD) patients with TDP43 pathology (n=12), eight 
FTD patients with tau pathology and 10 individuals with subjective memory complaints were 
recently described [19]. Among 56 proteins that differed between the patient groups, five 
were analyzed in a second cohort by enzyme-linked immunosorbent assay (ELISA), resulting 
in the confirmation of one; YKL-40 as a promising marker to distinguish the pathologies. 
YKL-40 is actually one of very few biomarkers that have shown consisting results across 
different studies and it was first identified as a biomarker for AD in 2010 by using two-
dimensional difference gel electrophoresis and LC-MS/MS [20].   Recently it was shown in a 
meta-analysis that the CSF YKL-40 concentrations are moderately increased in AD compared 
to controls (effect size 1.29) [11].  
Isobaric labeling 
Quantitative proteomic analysis by isobaric labeling is based on labeling the sample proteins, 
after tryptic digestion, with a reagent that contains heavy isotopes (13C, 15N). The reagent 
exists in different isobaric forms in which the heavy isotopes are differently distributed 
between a reporter group and a mass balance group. Upon MS/MS fragmentation, the 
reporter group is released and detected at its specific mass-to-charge (m/z). Because the 
reporter m/z is unique for each form of the reagent, differently labeled samples can be 
combined in a multiplex. Using the tandem-mass tag (TMT) method with 10-plex analysis, 
isobaric labeling shortens analysis times and enables larger clinical studies to be performed. 
Using isobaric labeling in a discovery proteomic study of patients suffering from delirium; a 
risk factor for development and progression of dementia, and patients with mild AD, changes 
in several protein family groups were reveled, including apolipoproteins, 
secretogranins/chromogranins and clotting/fibrinolysis factors [21]. 
Mer TMT/iTRAQ-studier??? 
Endopeptidomics 
While most CSF proteomic biomarker studies to date follow the standard procedure of 
digesting the sample proteins with trypsin prior to LC-MS, increasing attention is paid to the 
low-molecular weight polypeptides in CSF – the CSF endopeptidome. Recent studies have 
revealed that CSF contains a large number of endogenous peptides potentially reflecting a 
multitude of processes in the brain, such as enzymatic activity and secretion. Thus, 
endogenous peptides may represent an important source of disease biomarkers [15,22,23]. In 
a recent study, over 18,000 endogenous CSF peptides were identified, among which were 
peptides derived from the core AD biomarkers tau and Aβ. Having molecular masses below 
10 kDa, endogenous peptides can easily be separated from the larger, high-abundant proteins 
that make up the bulk protein mass in CSF, such as albumin and immunoglobulins, improving 
mass spectrometric detection sensitivity. They can be directly analyzed by MS, without prior 
tryptic digestion, simplifying sample preparation, and removing a potential source of 
variation.  
Using a sample preparation protocol for fractionating endogenous peptides in CSF the 
endopeptidome of postmortem CSF from neuropathologically confirmed AD patients and 
non-demented controls was analyzed [24]. The protocol was based on a step-wise partial 
protein- and peptide precipitation and resolubilization, and subsequent analysis by CE-MS. 
Peptides from several proteins that have previously been reported to be altered in AD were 
identified, including neurosecretory protein VGF, Comp C4 andAlfa-2HS Glycoprotein. 
Using an integrated proteomic and endopeptidomic approach based on TMT labeling that 
enabled analysis of proteins and endogenous peptides to be performed on the same sample 
aliquot it was shown in a small pilot study comprising eight AD patients and eight non-
demented controls that endogenous peptides derived from ineurosecretory protein VGF, 
integral membrane protein 2B and metallothionein-3 were decreased in AD [23]. The same 
method was used in an AD treatment study of a γ-secretase inhibitor [25], in which alterations 
in the CSF endopeptidome were measured longitudinally following administration of the 
drug. Several peptides were detected that changed in abundance in a dose-dependent manner. 
Among these were found a fragment of Aβ and APLP1; known γ-secretase substrates, 
demonstrating the applicability of the approach. 
 
Targeted quantification by mass spectrometry 
 
Multiple reaction monitoring (MRM) mass spectrometry is a highly sensitive and selective 
method which can be used for targeted quantitation of protein/peptide abundances in complex 
biological samples such as CSF. In an MRM experiment, the first mass analyzer selects a 
precursor ion (the protein or peptide of interest) which is fragmented. The fragment ions are 
then measured and recorded in the second mass analyzer. By adding isotopic labelled version 
(e.g., 13C and/or 15N) of the peptide of interest prior to any sample preparation, absolute 
quantification can be obtained. In a MRM or SRM experiment several different precursor ions 
can be monitored enabling quantification of multiple targets in a panel format. This approach 
was used to quantify Aβ1-38, Aβ1-40 and Aβ1-42 in two clinical materials, each consisting of 
15 AD patients and 15 cognitively normal controls using solid-phase extraction and isotopic 
labelled variants of the target peptides for absolute quantification. There was a moderate to 
good correlation between the SRM method and ELISA with similar sensitivities and 
specificities (80% and above). The LC-MS Aβ1-42 concentrations were however 
approximately twice as high compared to the ELISA measurements. Using the Aβ1-42/Aβ1-
40 ratio showed an improved separation between AD and controls [26]. An optimized and 
thoroughly validated method for quantifying Aβ1-42 is now accepted as a reference 
measurement procedure (RMP) by The Joint Committee for Traceability in Laboratory 
medicine (JCTLM) [20]. A similar method for Aβ1-42 has also been accepted as a RMP [27]. 
In a cross validation study consisting of 100 non-demented patients with mild cognitive 
complaints, the RMP Aβ1-42 showed a good agreement with cortical Aβ deposition 
determined using amyloid positron emission tomography (PET). Sensitivities and specificities 
were more than 80% when using only Aβ1-42 , and more than 90% when using the CSF Aβ1-
42/Aβ1-40 ratio [28]. 
A method to measure the metabolism of Aβ1-38, Aβ1-40 and Aβ1-42 in vivo was achieved by 
infusing stable isotope labeled leucine intravenously for nine hours. CSF was then collected 
every hour for 36 hours and the rate of metabolism was measured as the labeled leucines were 
incorporated in the newly synthesized Aβ. All three Aβ peptides had the same rate of 
incorporation of measurable labeled leucine (after four hours) as well as peak level (between 
18 to 20 hours post infusion) before decreasing (21 to 32 hours post infusion) [29].  
Tau is an emerging protein for MRM analysis and different approaches have been used. Using 
antibodies to first enrich tau from CSF followed by digestion, a tryptic peptide common for 
all six human forms of tau was quantified using LC-MS/MS. Results showed a significant 
difference in tau concentrations between AD (n=50) patients and healthy controls (n=50). The 
method correlated well with Meso Scale Discovery total tau immunoassay [30]. Another 
approach is to enrich the tau proteoforms by SPE [31]. Seven tryptic peptides were measured 
using a triple quadrupole mass spectrometer, an instrument more common in clinical 
laboratories compared to high resolution instruments. While the results correlated well with 
ELISA methods the MRM concentrations obtained were 17-25 times higher. Only one of the 
seven peptides seems to reflect total tau, and the authors argue that the seven peptides can be 
used as independent biomarkers [32]. Recently, a PRM method to measure 18 peptides 
covering the entire tau protein using high resolution MS was developed in which protein 
precipitation followed by solid phase extraction (SPE) was used for sample cleanup [33]. The 
method was applied on a clinical cohort including of AD, progressive supranuclear palsy 
(PSP) and DLB. MS results showed a good correlation with ELISA measurements, while MS 
values were about 20 times higher. Results showed that not only the central core of the tau 
protein but also peptides along the entire protein was increased in AD. 
Synaptosomal-associated protein 25 (SNAP-25) is a marker of functional synapses since it 
mediates communication by initiating fusion of synaptic vesicles and it has been hypothesized 
that soluble forms of brain SNAP-25 resembles SNAP-25 in CSF. Indeed, the levels of tryptic 
peptides of SNAP-25 were increased in AD compared to non-demented controls in three 
cohorts (including very early stages of AD). These findings imply that CSF SNAP-25 might 
be used to follow the progression of cognitive decline [34]. Similarly, in a study comprising 
patients with MCI due to AD, patients with dementia due to AD and controls the pre-synaptic 
protein synaptotagmin-1 was analyzed. The levels of synaptotagmin-1 were increased in the 
MCI and AD compared with controls, where the highest levels were in the MCI group (only 
in one of two sample set) and it was suggested that that the synaptic degeneration can be 
identified in preclinical AD [35]. 
The APOE ε4-allele is strongly associated with AD and is the best established genetic 
association with AD [36]. Despite intensive research has been conducted to shed light on how 
ApoE contributes to the AD pathology, where the risk of developing AD is approximately 15 
times higher in homozygotes of the 4 allele compared with non-carriers [26], has the 
mechanism not yet been elucidated. In order to investigate if ApoE can be used as a 
biomarker for AD, an SRM method to measure the different ApoE isoforms in human CSF 
was developed. One peptide for each isoform was quantified. The extent of methionine 
oxidation, glutamine deamidation and cyclization of N-terminal carbamidomethylcysteine 
was also studied. Despite good validation results the correlation between SRM and ELISA 
was moderate [37]. The same method was later used to measure ApoE isoforms (ApoE2, 
ApoE3 and ApoE4) in CSF from AD patients and non-AD individuals. However, the results 
showed no difference in ApoE concentrations between the groups [38]. 
Ubiquitin has been associated with several diseases including AD. Recently a method to 
quantify free monoubiquitin in CSF was developed. The intact protein was measured since 
enzymatic digestion would not be useful as the information of the ubiquitin form would be 
lost. Results from the study showed an increased concentration of ubiquitin in CSF in AD (as 
well as Creutzfeldt–Jakob disease (CJD) compared to controls and other neurodegenerative 
diseases, which the authors use to argue that there might be an AD specific process for the 
increase [39]. 
Mutations in the TREM2 gene have been shown to be associated with an autosomal recessive 
form of early-onset dementia [40]. In a discovery cohort including 37 AD and 22 controls and 
in a follow-up study comprising 24 AD and 16 controls, a statistically significant increase of 
CSF soluble TREM2 (sTREM2) in AD patients was observed, but with a large overlap 
between AD and controls. Thus, sTREM2 does not seem to be useful as a diagnostic tool but 
rather to study inflammation and glial activation, unrelated to Aβ pathology (since sTREM2 
did not correlate with Aβ1-42) [41]. 
Based on the core CSF AD biomarker profiles (Aβ1-42, T-tau and P-tau measured with 
ELISA) a cohort of AD (14) and controls (14) were selected and analyzed using PRM for 
lysosome-associated membrane protein 2 (LAMP2). The levels of all three peptides were 
reported to increase in AD compared to controls. LAMP2 did not correlate with any of the 
AD core biomarkers [42]. 
Several highly multiplexed MRM methods have also been reported in attempt to narrow in on 
new potential biomarkers for AD. By analyzing 25 peptides corresponding to 16 candidate 
biomarkers, selected from previously published data from 2D gel electrophoresis and matrix-
assisted laser desorption/ionization (MALDI)-time-of flight (TOF), it was shown that 12 of 
the 16 target proteins were consistent with the literature regarding up- or down regulation in 
AD [43]. However, due to the low patient number (three AD and three normal subjects) the 
study needs to be replicated in a larger independent cohort. This method was later modified to 
use micro LC instead of nano LC [44]. In another study, 39 peptides corresponding to 30 
proteins (selected from published proteomic discovery experiments) were quantified 
longitudinally over four years. While APP, transthyritin,  YKL-40, complement component 
C3, prostaglandin-d2 synthase and ApoE exhibited differences between AD and Co, AD and 
MCI or MCI and Co, longitudinal results showed a reduction for neuronal pentraxin receptor, 
NrCAM and chromogranin A overtime [45]. Finally, a method to measure 320 peptides from 
142 proteins was used to analyze samples from the AD Neuroimaging Initiative consisting of 
AD (n=66), Co (n=85) and MCI (n=134). Peptides from hemoglobin A and B, superoxide 
dismutase, neuronal pentraxin-2, neurosecretory protein VGF and secretogranin-2 showed a 
significant difference between progressors and nonprogressors in the MCI group. [46]. 
 
Targeted enrichment by immunoprecipitation – mass spectrometry 
Affinity purification or immunoprecipitation (IP) with monoclonal or polyclonal antibodies 
combined with characterization and quantification of eluted proteins and peptides with MS is 
one variant of targeted proteomics. The antibodies, directed towards a protein or family of 
proteins, can be bound to different media, e.g., magnetic beads, plate surfaces or columns to 
selectively purify and concentrate the target analyte. The eluate is then analyzed most 
commonly with LC-MS but MALDI TOF/TOF has also been used. The advantage of IP-MS is 
that the purification often is highly selective making it possible to extract a particular protein 
or protein family from a very complex sample matrix such as plasma, tissue, or CSF. The results 
from IP-MS studies can also be utilized to guide development of ELISAs or other immunoassay 
that target a particular protein form. Moreover, IP-MS makes it possible to characterize and 
simultaneously quantify several different forms of the target protein. The main disadvantage is 
that the method depends on the existence of a suitable antibody aimed at the protein of interest. 
In addition, if antibodies directed towards a particular protein are available efforts are often 
directed towards developing an immunoassay instead of a hybrid method such as IP-MS. 
 
A major drive in IP-MS has been to target proteins that are related to the AD pathology 
including different forms of Aβ and its precursor, amyloid precursor protein (APP) [47]. Several 
studies have identified and characterized many different forms of Aβ in CSF, brain tissue, and 
plasma. The CSF concentrations of several of these have been shown to be influenced by drugs 
and disease processes [48]. A recent example of an ELISA developed because of results from 
IP-MS is the study by Perez-Grijalba et al. where they developed an ELISA being able to 
selectivity measure Aβ1-17 both in CSF and plasma. 
 
It has been known for 20 years that several synaptic proteins can be detected in CSF [49] and 
that synaptic dysfunction and loss are directly linked to memory disturbances at the early stages 
of AD [50-53]. Several studies have used IP-MS to study synaptic pathology by characterizing 
and quantifying presynaptic proteins in CSF. Neurogranin, a postsynaptic protein, is an example 
of a hypothesis driven workflow. In 2010, it was shown by semi-quantitative western blotting 
that CSF neurogranin is increased in AD compared to healthy controls [54]. Recently, it was 
shown in two independent pilot studies by IP-MS that CSF neurogranin is expressed as a variety 
of small endogenous peptide fragments (in addition to full-length protein) of which the 
concentration of peptide Ng48-76 was significantly increased in AD compared to controls [55]. 
In addition, it has also been shown that some of the neurogranin peptides are unique for plasma 
and not detectable in CSF and the other way around [56]. Based on these findings, novel anti-
neurogranin antibodies and an ELISA were developed. It was then shown that CSF neurogranin 
is increased already at the early clinical stages of AD and predicts cognitive deterioration and 
disease-associated changes in metabolic and structural biomarkers over time [57]. Today, 
several studies have confirmed the use of neurogranin to aid to the AD diagnosis and in Sweden 
the ELISA is currently introduced into the clinic for routine analysis. Recently it was shown by 
IP-MS in three separate cohorts that the CSF concentration of a fragment from the presynaptic 
protein SNAP-25 was significantly higher in AD compared to controls, also at the very early 
stages of the disease, showing its value as a marker for synaptic integrity [58]. Another synaptic 
protein, synaptotagmin-1, appears to be essential for the maintenance of an intact synaptic 
transmission and cognitive function. Using IP-MS is has been shown in two independent sample 
sets that the CSF concentration of synaptotagmin-1 was significantly increased in patients with 
dementia due to AD and in patients with mild cognitive impairment due to AD compared to 
controls [59]. In addition, in sample set I the synaptotagmin-1 concentration was significantly 
higher in patients with mild cognitive impairment due to AD compared with patients with 
dementia due to AD. Thus, CSF neurogranin, SNAP-25, and synaptotagmin-1 are promising 
biomarkers to monitor synaptic dysfunction and degeneration in AD. 
Besides plaques, tangles, and synaptic pathology there is an increasing body of evidence 
suggesting that endo-lysosomal dysfunction is a pathogenic mechanism of AD [22]. Hence, 
proteins involved in the normal function of endo-lysosomal vesicles could be tentative 
biomarkers of AD. The lysosomal protein LAMP2 is involved in chaperone mediated 
autophagy and recently it was shown that the concentrations of three CSF LAMP2 peptides 
were increased in AD compared to non-AD controls [42]. Altered CSF LAMP2 concentrations 
may indicate endo-lysosomal dysfunction in AD, but further studies of larger cohorts also 
including patients with other neurodegenerative disorders are required. 
Lately, several methodological studies focusing on reproducibility and co-IP in affinity-
purifications have been published [60]. Quantitative affinity purification mass spectrometry: a 
versatile technology to study protein–protein interactions Front Genet. 2015; 6: 237.). Efforts 
have also been put into standardizing the methods and checking reproducibility across 
laboratories (Aebersold igen). However, even if IP-MS has been used in several studies 
showing potentially promising results, for AD there is still no IP-MS method that has been fully 
validated and introduced to clinical use. 
 
Other targeted and functional proteomic approaches 
Another approach to focus on a subset of the CSF proteome is to either investigate specific 
protein interactions or specific functional groups. There are, however, only a few published 
studies employing these approaches. For example, using IP to isolate binding partners to Aβ, 
seven proteins that bind specifically to Aβ1-40 were identified [61]. Of the seven proteins, the 
protein Dkk-3 was selected for further investigation with ELISA. However, no difference was 
found when comparing CSF from AD and control subjects. 
 
Making use of a redox proteomics approach by using 2D-gels with immunoblotting of 
carbonyl-modified CSF proteins, proteins which may be linked to oxidative stress and (early) 
AD have been identified [62]. MALDI fingerprinting was used to identify the proteins and 2D 
Western blot was used for quantification. This investigation points at early protein oxidative 
events in AD compared to MCI and controls with several proteins upregulated in AD. 
However, the small N (6+6+6) means that the finding needs to be replicated. 
 
A number of Aβ peptides were discovered to also occur in various O-glycosylated forms in 
CSF [63]. The O-glycosylated Aβ peptides belonged to two distinct groups; one consisting of 
peptides spanning the β-secretase cleavage site with C-termini ending at Gln15 of Aβ and one 
consisting of short Aβ peptides with N-termini at Asp1 of Aβ. The latter group exhibited a 
number of different glycans situated at Tyr10. Quantification was performed using label free 
LC-MS after IP with the anti-Aβ antibody 6E10. In a small cohort of 6 AD + 7 non-AD 
subjects higher CSF concentrations of the Tyr10 glycolsylated Aβ forms in AD compared to 
the non-AD controls was reported. This finding also needs replication in a larger material and 
with a method better suited for quantification. In another type of glycosylation study CSF 
samples were subjected to PNGaseF to cleave off N-glycans from their proteins. Subsequently 
a number glycans were identified that differed in concentration between AD/MCI and 
controls [64]. They used PCS analysis to make a model and then employed the model to 
divide the AD and MCI groups into subgroups. While one of the AD/MCI subgroup differed 
little from controls, the other exhibited good separation. 
 
By a combined isobaric TMT labeling with subsequent IP using anti-Aβ antibodies, a cohort 
of 8 AD, 11 MCI, and 19 controls has been analyzed by LC-MS/MS operated in data 
dependent mode [65]. Although none of the detected peptides can be used as a biomarker for 
AD, this is a promising approach and allowed parallel relative quantification of 27 Aβ 
peptides. The described approach could also allow for analysis of post-translationally 
modified peptides such as glycans. Possible disadvantage is the labeling cost and the quality 
of the quantification compared to SRM/PRM, but it should work to perform the LC-MS/MS 
in a targeted way to improve robustness and sensitivity; of course at the expense of number of 
analytes measured. 
 
In in vitro experiments on Aβ oligomerisation, auto-cleavage was observed to produce Aβ1-
23, Aβ 1-24, and Aβ1-25 [66]. After development of an AβX-25 neospecific antibody, these 
fragments were proven to be present in both brain and CSF. CSF from a cohort of 16 AD and 
14 non-demented control subjects was investigated by SRM but no difference between the 
groups was observed.  
 
Expert commentary: the author’s expert view on the current status of the field under 
discussion.  
Despite nearly two decades of research, including explorative mass spectrometric studies and 
targeted approaches (e.g., SRM/PRM and immunoassays), proteomic analysis in CSF has 
failed to identify any new clinically useful biomarkers for AD. While several biomarker 
candidates have been identified, none have yet reached the clinic to aid to the AD diagnosis. 
Discovering new CSF biomarkers has obviously turned out to be difficult, and the current 
trend is that while the use of LC-MS in CSF analysis is steadily increasing since the 
beginning of the century, the number of CSF proteomic studies per year has leveled out in the 
last five years and may in fact be decreasing (Figure 1). 
 What is lacking in several published studies is validation of the potential biomarker in an 
independent cohort using an independent method. However, it may be difficult for a 
proteomic laboratory to gain access to well characterized AD and control materials, and 
repeating a study in an independent cohort may be even more challenging. Thus, what is 
needed is closer collaboration between proteomic research groups and clinics. 
What is evident in the panel approaches, including both mass spectrometry and immunoassay 
studies, is that the same “usual suspects” are interrogated over and over again. For example, 
apoE, clusterin, chromogranin, secretogranin, neurosecretory protein VGF, VEGF, 
transthyretin, and HFABP have been reported in several proteomics studies with varying 
results, and yet none of these potential biomarkers has reached the clinic. One reason may be 
lack of validation studies, as mentioned above. Also, many of these proteins have turned up as 
biomarker candidates of other neurodegenerative disorders, suggesting that they may reflect 
processes downstream to the core pathology, and thus not by highly specific to AD.  
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It is noteworthy that all these proteins are fairly high-abundant and have been identified in 
early discovery studies. Improved detection sensitivity of mass spectrometers, improved LC 
performance, and improved sample preparation methods are making it possible to detect 
lower-abundant CSF proteins, which may lead to the identification of low abundant proteins 
that might be more directly involved in the disease process, Recent examples include mapping 
of the phosphorylation sites of CSF tau (Russell CL et al. 2016), Lehmann, Anns Snare 
complex, CSF exosomes, the identification of endogenous tau peptides (Karl 2017). 
Also evident from the literature is that, apart from highly targeted sets of biomarkers (e.g., 
enzymes and metabolites that reflect liver function and a complete blood count that reflects 
various hematological conditions), there is actually no panel for multiple biomarkers in 
clinical use for any disease. Thus, AD is in good company. There are many possible 
explanations for this; the most obvious being that the biomarkers are not adding any 
additional disease specific information for the AD diagnosis; they still may separate AD from 
control statistically but the overlap between the groups investigated is too large for the 
biomarker to be of clinical usefulness. Another explanation could be that in proteomic and 
panel studies are often several analytes monitored in the same study setting. Thus, to find a 
significant change in the levels of a novel biomarker among several identified, the sample set 
has to be rather big in order to pass correction of the p-value for multiple testing. In order to 
identify new biomarker targets, validate them, and implement them into the clinic, the 
proteomic field may have reconsider the workflow from the discovery phase to the clinic. The 
work flow can divided into explorative driven work flow and hypothesis driven work flow. 
Even though the two work flows have different starting points, the two pathways will 
converge at the development of assays which are suitable for the clinic. 
Several proteomic studies have applied digestion of the samples using, e.g., trypsin prior to 
mass spectrometric analysis and in order to detect as many tryptic peptides as possible, long 
gradients are used. But what is gained in sensitivity by this approach is not unlikely lost in 
disease specific information regarding endogenous peptides. Similarly, when it was 
discovered that Aβ can be measured in CSF, no clear difference in the concentrations between 
AD and controls was obtained. This was due to that total Aβ was measured; however, when a 
selective method for measuring Aβ42 was developed, a marked decrease was evident in AD 
patients.  
Today immunoassays are often the method of choice when introducing a method into the 
clinic. However, the ELISA methods used for AD are not yet fully standardized, which 
influences the apparent concentration measured. In addition, immunoassays suffer from 
matrix effects and differences in assay calibrations. There is ongoing work in different 
consortia. Both the Alzheimer’s Association Quality Control program for CSF biomarkers 
and the International Federation of Clinical Chemistry Working Group for CSF proteins have 
the goal to harmonize these assays. Recently, a mass spectrometry-based reference 
measurement procedure (RMP) for absolute quantification of Aβ1-42 in CSF was developed 
which will be used by kit vendors to harmonize the different ELISAs on the market. However, 
what is gained in specificity, reduced matrix effects, and the possibility of using panels of 
many target molecules within a single analysis using the RPM is lost regarding sample 
throughput when comparing to state-of–the-art immunoassay methods.  
 
Five-year view: a speculative viewpoint on how the field will evolve in 5 years’ time.  
It is well established that AD includes several pathologies besides plaques and tangles. 
Whereas we have quite good biomarkers for neurodegeneration and plaque and tangle 
pathology in AD, we currently lack biomarkers for other neuropathological changes that are 
common in neurodegenerative diseases. We encourage intensified efforts to find reliable fluid 
biomarkers for TDP-43 and -synuclein inclusions. In a five-year perspective we believe that 
there will be an extended panel of CSF biomarkers for neurodegenerative diseases that could 
be used to classify patients with cognitive symptoms into biomarker categories based on what 
pathology (or combination of pathologies) that is most likely to drive the symptoms. Such a 
panel could be immunochemical or based on targeted MS analysis of the sample and could 
also include markers that reflect microglial activation, synaptic dysfunction, apoE phenotype, 
as well as markers that may indicate resilience or protective factors.  This will be of outmost 
importance when we have a treatment having a disease modifying effect since we need to 
know not only if the patient has AD; we also need to know the comorbidity so the patients are 
given proper treatment.  
 
The knowledge gained from Aβ, tau, and neurogranin (and many other proteins) has driven 
the proteomics towards peptidomics since we know that many of the proteins are expressed as 
endogenous peptides which may hold more disease specific information than the full length 
protein itself.      
 
Key issues: 8–10 bullet points summarizing the review.  
 Proteomic analysis in CSF has failed to identify any new clinically useful biomarkers of AD. 
 Closer collaborations between proteomic research groups and clinics are needed. 
 Several of the identified proteins are most not likely not specific for AD  
 In order to identify low abundant proteins improved detection sensitivity of mass 
spectrometers, improved LC performance, and improved sample preparation methods are 
required.  
 Today there is no CSF panel for multiple biomarkers in clinical use for any disease. 
 In order to identify new biomarker targets, validate them, and implement them into the clinic, 
the proteomic field may have reconsider the workflow from the discovery phase to the clinic. 
 Endogenous peptides may hold more disease specific information than the full length 
protein itself.      
 Comorbidity (the presence of more than one disease process) is present in more than half of 
the AD patients. 
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